Publications by authors named "D Harada"
High-energy nuclear collisions create a quark-gluon plasma, whose initial condition and subsequent expansion vary from event to event, impacting the distribution of the eventwise average transverse momentum [P([p_{T}])]. Disentangling the contributions from fluctuations in the nuclear overlap size (geometrical component) and other sources at a fixed size (intrinsic component) remains a challenge. This problem is addressed by measuring the mean, variance, and skewness of P([p_{T}]) in ^{208}Pb+^{208}Pb and ^{129}Xe+^{129}Xe collisions at sqrt[s_{NN}]=5.
View Article and Find Full Text PDFArticle Synopsis
- Patients with generalized myasthenia gravis (gMG) face serious physical and social challenges, and while immunotherapy has been common, not all patients find relief.
- Recent advancements have led to the development of new therapies like efgartigimod alf a, which is an intravenous treatment, now combined with vorhyaluronidase alfa for easier subcutaneous administration and better absorption.
- Clinical trials, including the ADAPT-SC study, show that this new subcutaneous treatment is as effective as the intravenous form, with promising long-term safety and benefits, making it more convenient for patients and healthcare providers.
Local failure of non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) often occurs within 2 years and delayed local failure is uncommon. In the present study, features of late local failure (LLF; >2 years after SBRT) after SBRT were investigated and compared with those of early local failure (ELF; ≤2 years after SBRT) to explore whether these two local recurrence features have different prognostic implications. Patients who underwent SBRT for stage I-IIA NSCLC between July 2006 and March 2014 were retrospectively reviewed.
View Article and Find Full Text PDFA search for the exclusive hadronic decays W^{±}→π^{±}γ, W^{±}→K^{±}γ, and W^{±}→ρ^{±}γ is performed using up to 140 fb^{-1} of proton-proton collisions recorded with the ATLAS detector at a center-of-mass energy of sqrt[s]=13 TeV. If observed, these rare processes would provide a unique test bench for the quantum chromodynamics factorization formalism used to calculate cross sections at colliders. Additionally, at future colliders, these decays could offer a new way to measure the W boson mass through fully reconstructed decay products.
View Article and Find Full Text PDFArticle Synopsis
- - The ATLAS experiment at the LHC conducted a search for long-lived particles (LLPs) using a large dataset (140 fb^{-1}) from proton-proton collisions at 13 TeV, focusing on LLPs with masses from 5 to 55 GeV that decay within the inner detector.
- - The study considered scenarios where LLPs are produced from exotic Higgs boson decays and models involving axionlike particles (ALPs).
- - No significant findings above expected background levels were detected, leading to the establishment of upper limits on various production rates involving the Higgs boson and the top quark related to LLPs and ALPs.